Title |
Development of prophylactic vaccines against HIV-1
|
---|---|
Published in |
Retrovirology, July 2013
|
DOI | 10.1186/1742-4690-10-72 |
Pubmed ID | |
Authors |
Torben Schiffner, Quentin J Sattentau, Lucy Dorrell |
Abstract |
The focus of most current HIV-1 vaccine development is on antibody-based approaches. This is because certain antibody responses correlated with protection from HIV-1 acquisition in the RV144 phase III trial, and because a series of potent and broad spectrum neutralizing antibodies have been isolated from infected individuals. Taken together, these two findings suggest ways forward to develop a neutralizing antibody-based vaccine. However, understanding of the correlates of protection from disease in HIV-1 and other infections strongly suggests that we should not ignore CTL-based research. Here we review recent progress in the field and highlight the challenges implicit in HIV-1 vaccine design and some potential solutions. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Mexico | 1 | 17% |
Canada | 1 | 17% |
United States | 1 | 17% |
Unknown | 3 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 83% |
Science communicators (journalists, bloggers, editors) | 1 | 17% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 1 | <1% |
Ireland | 1 | <1% |
Gambia | 1 | <1% |
India | 1 | <1% |
United States | 1 | <1% |
Unknown | 138 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 26 | 18% |
Student > Ph. D. Student | 24 | 17% |
Researcher | 24 | 17% |
Student > Master | 23 | 16% |
Student > Postgraduate | 9 | 6% |
Other | 23 | 16% |
Unknown | 14 | 10% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 45 | 31% |
Medicine and Dentistry | 40 | 28% |
Immunology and Microbiology | 17 | 12% |
Biochemistry, Genetics and Molecular Biology | 13 | 9% |
Engineering | 4 | 3% |
Other | 10 | 7% |
Unknown | 14 | 10% |